Meeting
2023 ASCO Annual Meeting
Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Authors
Carmen Julia Calfa
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
Carmen Julia Calfa , Michael Rothe , Gordan Srkalovic , Herbert Leon Duvivier , Deepti Behl , J Michael Straughn , Kathleen J Yost , Inderjit Mehmi , Evan P. Pisick , Bhavina B Sharma , Ramya Thota , Dan Steven Veljovich , Olatunji B. Alese , Timothy Lewis Cannon , Anu G. Gaba , Walter John Urba , Margaret von Mehren , Gina N. Grantham , Susan Halabi , Richard L. Schilsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Clinical Trial Registration Number
NCT02693535
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3117)
DOI
10.1200/JCO.2023.41.16_suppl.3117
Abstract #
3117
Poster Bd #
315
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
First Author: Gordan Srkalovic
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: Jean L. Grem
Poster
2021 ASCO Annual Meeting
Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: Evan P. Pisick
Poster
2020 Gastrointestinal Cancers Symposium
Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
First Author: Eyal Meiri